119 HR 796 IH: Second Chance for Moms Act U.S. House of Representatives 2025-01-28 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I119th CONGRESS1st SessionH. R. 796IN THE HOUSE OF REPRESENTATIVESJanuary 28, 2025Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of Alabama, Mr. Moore of West Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. Tenney, Mr. Clyde, Mr. Harris of Maryland, and Mr. Weber of Texas) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.

1.

Short title

This Act may be cited as the Second Chance for Moms Act of 2025.

2.

Mifepristone warning label and hotline

(a)

Warning label

(1)

In general

Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following:(hh)If it is the drug mifepristone, and its labeling does not bear the following statement printed in conspicuous text: WARNING: Medical evidence suggests that the abortifacient effects of mifepristone can be counteracted by natural progesterone, which can increase the chance of fetal survival. The American Society for Reproductive Medicine has determined that natural progesterone is safe in the first trimester of pregnancy. For more information, call [___]. (with the blank filled in to refer to the appropriate number for the hotline under section 1009 of the Public Health Service Act)..(2)

Effective date

Section 502(hh) of the Federal Food, Drug, and Cosmetic Act (as added by paragraph (1)) applies beginning on the date that is 6 months after the date of enactment of this Act.(b)

Hotline

Title X of the Public Health Service Act (42 U.S.C. 300 et seq.) is amended by adding at the end the following:

1009.

Hotline for reversal of effects of mifepristone

(a)

In general

The Secretary shall establish or maintain, directly or by grant or contract, a toll-free hotline to provide support for 24 hours a day, 7 days a week, for women seeking to reverse the effects of the drug mifepristone.(b)

Referrals to APR providers only

A referral through the hotline described in subsection (a) may only be made to a health care provider that provides abortion pill reversal services.

.